Could BD be ripe for pick-up?

Becton Dickinson ($BDX) is witnessing successive profit declines for the first time in at least two decades, raising the possibility of an acquisition by the likes of Johnson & Johnson ($JNJ) or private equity firms, according to Haverford Trust and Edward Jones & Co. "Becton is an undervalued company with a tremendous franchise," Hank Smith, chief investment officer at Haverford Trust, said in a telephone interview with Bloomberg. "If Becton gets too much cheaper than this it might very well find itself an acquisition target." News

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.